Fatty Bases for Suppositories Market , by Excipient Base Type [Hard fat, Macrogol (PEG), Glycerol+Water, Gelatin, Cocoa Butter], Regional Analysis (North America, Europe, Asia Pacific, LAMEA): Global Opportunity Analysis and Industry Forecast, 2019–2027
- RES4072092
- 197 Pages
- September 2020
- Healthcare
Suppositories (excipients) are solid or semi-solid dosages of various shapes and weights, adapted for introduction into the vaginal or rectal openings of the human body. This excipient melt, soften, or dissolve at body temperature and also act as a carrier of therapeutic agents for systemic action.
The fat-based suppositories play a crucial role in drug delivery, majorly in geriatric and pediatric patients. The rectal route serves as an excellent alternative for drug delivery amongst these populations. In addition, the increasing demand for fat-based excipients is mainly due to their benefits such as the potential for absorption into the lymphatic system, and quick absorption of multiple low molecular weight drugs. Moreover, the increasing number of product launches are anticipated to generate a lucrative opportunity for the growth of the global market. For instance, in July 2017, Cipla launched fat-based rectal suppositories for the treatment of malaria. These factors may lead to driving the growth of global fatty bases for suppositories market, over the forecast period.
On the other hand, the complexities in the developing of oil-based suppositories are expected to restrain the growth of the market, during the analysis period.
The highly advanced healthcare sectors are seeking a better alternative and enhanced medication that could effectively help patients to recover from infectious diseases. Continuous research work across majority of countries by multiple institutions shows a positive chance of designing antiretroviral suppository drug delivery medication. These delivery systems are being developed majorly and offer efficient and cost-effective options for high-risk patients. Due to such factors, the need for fat-based suppositories will increase extensively across the globe.
Hard fat has the biggest market share in 2020 and they are anticipated to generate a revenue of $3,039.1 million by 2027, increasing from $2,385.4 million in 2019; this is mainly owing to several versatile properties of hard fat . On the other hand, glycerol+water suppositories shall have the fastest growth and they are anticipated to register a revenue of $173.1 million by 2027, increasing from $120.3 million in 2019.
Europe region fatty bases for suppositories market share is expected to increase at a growth rate of 3.2% by registering revenue of $1,981.3 million by 2027. The fatty bases for suppositories market size in North America generated a revenue of $1,988.5 million in 2019 and it is projected to account for $2,410.2 million by 2027;
Some of the significant Fatty bases for suppositories industry players include Bliss GVS Pharma Ltd., Unither, ATRAL, Priyans Drugs, Delpharm, FAMAR, Aenova Holding GmBH, and LGV (Laboratories Mayoly Spindler). Fatty bases for suppositories industry players are mainly focusing on advanced product developments, and strategic mergers & acquisitions.
1.1. Research methodology
1.1.1. Desk research
1.1.2. Real-time insights and validation
1.1.3. Forecast model
1.1.4. Assumptions & forecast parameters
1.1.4.1. Assumptions
1.1.4.2. Forecast parameters
CHAPTER 2: EXECUTIVE SUMMARY
2.1. 360° summary
2.2. Excipient base type trends
CHAPTER 3: MARKET OVERVIEW
3.1. Market segmentation & definitions
3.2. Key takeaways
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Superior procedural outcomes to drive the market growth
3.4.1.2. Aging population
3.4.2. Restraints
3.4.2.1. Reluctance of patients to prefer rectal drug delivery
3.4.3. Opportunities
3.4.3.1. Antiretroviral suppository drugs to treat viral infections to create lucrative market opportunities
3.5. Regulatory landscape
3.6. Patent landscape
3.7. Market value chain analysis
3.8. Strategic overview
CHAPTER 4: IMPACT OF COVID19 ON GLOBAL FATTY BASES FOR SUPPOSITORIES MARKET
4.1. Introduction
4.2. COVID-19 health assessment
4.3. Impact of COVID-19 on the global economy
4.4. Impact of COVID-19 on global fatty bases for suppositories market
4.4.1. Social impact
4.4.2. Technological impact
4.4.3. Investment scenario
4.5. Fatty bases for suppositories market size and forecast, by region, 2019-2021
CHAPTER 5: GLOBAL FATTY BASES FOR SUPPOSITORIES MARKET, BY EXCIPIENT BASE TYPE
5.1. Overview
5.1.1. Market size and forecast, by excipient base type
5.2. Hard fat
5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country
5.3. Macrogol (PEG)
5.3.1. Market size and forecast, by region
5.3.2. Market share analysis, by country
5.4. Glycerol + water
5.4.1. Market size and forecast, by region
5.4.2. Market share analysis, by country
5.5. Gelatin
5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country
5.6. Cocoa butter
5.6.1. Market size and forecast, by region
5.6.2. Market share analysis, by country
CHAPTER 6: GLOBAL FATTY BASES FOR SUPPOSITORIES MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast, by region
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by excipient base type
6.2.3. Market size and forecast, by country
6.2.4. U.S.
6.2.4.1. Market size and forecast, by excipient base type
6.2.5. Canada
6.2.5.1. Market size and forecast, by excipient base type
6.2.6. Mexico
6.2.6.1. Market size and forecast, by excipient base type
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by excipient base type
6.3.3. Market size and forecast, by country
6.3.4. Germany
6.3.4.1. Market size and forecast, by excipient base type
6.3.5. UK
6.3.5.1. Market size and forecast, by excipient base type
6.3.6. Spain
6.3.6.1. Market size and forecast, by excipient base type
6.3.7. Italy
6.3.7.1. Market size and forecast, by excipient base type
6.3.8. Russia
6.3.8.1. Market size and forecast, by excipient base type
6.3.9. Rest of Europe
6.3.9.1. Market size and forecast, by excipient base type
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by excipient base type
6.4.3. Market size and forecast, by country
6.4.4. China
6.4.4.1. Market size and forecast, by excipient base type
6.4.5. Japan
6.4.5.1. Market size and forecast, by excipient base type
6.4.6. India
6.4.6.1. Market size and forecast, by excipient base type
6.4.7. South Korea
6.4.7.1. Market size and forecast, by excipient base type
6.4.8. Australia
6.4.8.1. Market size and forecast, by excipient base type
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market size and forecast, by excipient base type
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by excipient base type
6.5.3. Market size and forecast, by country
6.5.4. Latin America
6.5.4.1. Market size and forecast, by excipient base type
6.5.5. Middle East
6.5.5.1. Market size and forecast, by excipient base type
6.5.6. Africa
6.5.6.1. Market size and forecast, by excipient base type
CHAPTER 7: COMPANY PROFILES
7.1. Unither
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.2. Bliss GVS Pharma Ltd.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Delpharm
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Key strategy moves and development
7.4. Atral
7.4.1. Company overview
7.4.2. Company snapshot
7.5. Aenova Holding GmbH
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. Famar
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. LGV (Laboratories Mayoly Spindler)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.8. Priyans Drugs
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Product portfolio
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
